Studies Show That Sucrose May Be Partly Responsible for Chronic Liver Disease in Children

According to a recent report in Medical Xpress, over twenty studies have indicated escalating events of nonalcoholic fatty liver disease (NAFLD) in children worldwide. In the United States, NAFLD heads…

Continue Reading Studies Show That Sucrose May Be Partly Responsible for Chronic Liver Disease in Children
Inventiva Introduces Design for its Phase III Nonalcoholic Steatohepatitis Trial
source: pixabay.com

Inventiva Introduces Design for its Phase III Nonalcoholic Steatohepatitis Trial

According to a story from dernieresactus.fr, the biopharmaceutical company Inventiva has recently announced plans for its upcoming phase III clinical trial. This trial will investigate its lead candidate lanifibranor as…

Continue Reading Inventiva Introduces Design for its Phase III Nonalcoholic Steatohepatitis Trial
HemoShear & Takeda Partnership Identifies New Drug Target for NASH
source: pixabay.com

HemoShear & Takeda Partnership Identifies New Drug Target for NASH

In a recent press release, biotechnology company HemoShear Therapeutics ("HemoShear") shared that the company, in collaboration with Takeda Pharmaceutical Company Ltd. ("Takeda") identified a novel therapeutic target for nonalcoholic steatohepatitis…

Continue Reading HemoShear & Takeda Partnership Identifies New Drug Target for NASH
VK2809 for NASH Significantly Reduces LDL Cholesterol, Liver Fat
source: pixabay.com

VK2809 for NASH Significantly Reduces LDL Cholesterol, Liver Fat

In November 2020, Viking Therapeutics ("Viking") shared insight into their metabolic disease program. According to Greg Zante, the Senior VP (SVP) of Finance for Viking, the company's treatment VK2809, licensed…

Continue Reading VK2809 for NASH Significantly Reduces LDL Cholesterol, Liver Fat

Owlstone Medical Announces Successful Study Using Breath Biopsy to Measure Liver Function

Owlstone Medical recently announced the success of its patient study demonstrating its Breath Biopsy®, using limonene as a biomarker in measuring liver function. The study demonstrated how exhaled limonene, a…

Continue Reading Owlstone Medical Announces Successful Study Using Breath Biopsy to Measure Liver Function
The TARGET-NASH Study Finds Prior Opioid Use Prevalent in NAFLD Patients
source: pixabay.com

The TARGET-NASH Study Finds Prior Opioid Use Prevalent in NAFLD Patients

Target RWE, an innovative health evidence solutions company based in Durham, North Carolina recently announced its current data from the study of nonalcoholic steatohepatitis (NASH) via PRNewswire. The study, entitled…

Continue Reading The TARGET-NASH Study Finds Prior Opioid Use Prevalent in NAFLD Patients
More Research Needed to Help Postmenopausal Females at Risk for Nonalcoholic Fatty Liver Disease
source: pixabay.com

More Research Needed to Help Postmenopausal Females at Risk for Nonalcoholic Fatty Liver Disease

by Natalie Homan from In The Cloud Copy A review article published in Endocrinology in August of this year highlights the fact that a female's risk of developing nonalcoholic fatty…

Continue Reading More Research Needed to Help Postmenopausal Females at Risk for Nonalcoholic Fatty Liver Disease

Non-alcoholic Fatty Liver Disease: Study of Children Receiving Standard of Care Lifestyle Advice

by Danielle Bradshaw from In The Cloud Copy It’s possible for fat to end up stored inside of the liver due to either obesity, diabetes, certain medications, or high cholesterol.…

Continue Reading Non-alcoholic Fatty Liver Disease: Study of Children Receiving Standard of Care Lifestyle Advice
Alnylam Submits a Clinical Trial Authorization Application for Their NASH Treatment
Source: Pixabay

Alnylam Submits a Clinical Trial Authorization Application for Their NASH Treatment

Alnylam Pharmaceuticals has submitted their clinical trial authorization (CTA) application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for their RNAi therapy, ALN-HSD, a treatment for nonalcoholic steatohepatitis (NASH).…

Continue Reading Alnylam Submits a Clinical Trial Authorization Application for Their NASH Treatment
Data Supports Tesamorelin as Effective for HIV-Associated NASH
Arcaion / Pixabay

Data Supports Tesamorelin as Effective for HIV-Associated NASH

  Biopharmaceutical company Theratechnologies Inc. recently announced that its therapy candidate tesamorelin is effective in the treatment of HIV-associated nonalcoholic steatohepatitis (NASH). According to new data, published in JCI Insight, tesamorelin…

Continue Reading Data Supports Tesamorelin as Effective for HIV-Associated NASH